Guanylyl Cyclase-A Inhibits Angiotensin II Type 1A Receptor–Mediated Cardiac Remodeling, an Endogenous Protective Mechanism in the Heart

Yuhao Li, MD, PhD; Ichiro Kishimoto, MD, PhD; Yoshihiko Saito, MD, PhD; Masaki Harada, MD, PhD; Koichiro Kuwahara, MD, PhD; Takehiko Izumi, MD; Nobuki Takahashi, MD; Rika Kawakami, MD; Keiji Tanimoto, MD; Yasuaki Nakagawa, MD; Michio Nakanishi, MD; Yuichiro Adachi, PhD; David L. Garbers, PhD; Akiyoshi Fukamizu, PhD; Kazuwa Nakao, MD, PhD

Background—Guanylyl cyclase (GC)-A, a natriuretic peptide receptor, lowers blood pressure and inhibits the growth of cardiac myocytes and fibroblasts. Angiotensin II (Ang II) type 1A (AT$_{1A}$), an Ang II receptor, regulates cardiovascular homeostasis oppositely. Disruption of GC-A induces cardiac hypertrophy and fibrosis, suggesting that GC-A protects the heart from abnormal remodeling. We investigated whether GC-A interacts with AT$_{1A}$ signaling in the heart by target deletion and pharmacological blockade or stimulation of AT$_{1A}$ in mice.

Methods and Results—We generated double-knockout (KO) mice for GC-A and AT$_{1A}$ by crossing GC-A–KO mice and AT$_{1A}$-KO mice and blocked AT$_{1}$ with a selective antagonist, CS-866. The cardiac hypertrophy and fibrosis of GC-A–KO mice were greatly improved by deletion or pharmacological blockade of AT$_{1A}$. Overexpression of mRNAs encoding atrial natriuretic peptide, brain natriuretic peptide, collagens I and III, transforming growth factors $\alpha$ and $\beta$, were also strongly inhibited. Furthermore, stimulation of AT$_{1A}$ by exogenous Ang II at a subpressor dose significantly exacerbated cardiac hypertrophy and dramatically augmented interstitial fibrosis in GC-A–KO mice but not in wild-type animals.

Conclusions—These results suggest that cardiac hypertrophy and fibrosis of GC-A–deficient mice are partially ascribed to an augmented cardiac AT$_{1A}$ signaling and that GC-A inhibits AT$_{1A}$ signaling-mediated excessive remodeling. (Circulation. 2002;106:1722-1728.)

Key Words: natriuretic peptides | angiotensin receptors | heart diseases | remodeling

Normal cardiac structure is maintained by a sophisticated set of mechanical and cellular “checks and balances.” A disturbance of these checks and balances induces a remodeling process, the distinguishing features of which are phenotypic modulation of various cell types; cellular hypertrophy and hyperplasia; and production, deposition, and degradation of extracellular matrix.$^4$ Many studies have demonstrated important roles of the local renin-angiotensin (Ang) II system (RAS) in cardiac remodeling under various basal or pathological conditions.$^2,3$ Ang II was implicated in the development of cardiomyocyte hypertrophy and cardiac fibrosis in humans and in animal models.$^4–6$ Most of the Ang II functions in the cardiovascular system are mediated through the Ang II type 1 (AT$_{1}$) receptor.$^7$ Treatments with ACE inhibitors or AT$_{1}$ blockers effectively lower blood pressure (BP)$^8,9$ and prevent or ameliorate myocardial hypertrophy.$^{10}$

Atrial natriuretic peptide (ANP) is a cardiac hormone that acts through guanylate cyclase A (GC-A) to lower BP and dilate blood vessels in vivo.$^{11,12}$ and to inhibit the growth of cardiac myocytes and fibroblasts in vitro.$^{13,14}$ Brain natriuretic peptide (BNP) also activates GC-A and has effects similar to those of ANP. As we$^{15}$ and others$^{16}$ have previously reported, mice lacking GC-A exhibit hypertension, cardiac hypertrophy, and interstitial fibrosis, suggesting the roles of GC-A in controlling BP and protecting the heart from abnormal remodeling. The mechanisms, however, especially for the cardiac protection of GC-A, are still unknown.

In the present study, we sought to determine whether the RAS plays a role in the cardiac pathology of GC-A–knockout (KO) mice and whether there is any functional antagonism between the RAS and GC-A pathways. To investigate this hypothesis, we adopted 2 kinds of blocking strategies, genetic and pharmacological, because of the advantages of each. Targeting disruption of the GC-A gene can lead to complete blockade throughout life, but pharmacological blockade cannot. In contrast, pharmacological blockade can be applied after the development of cardiac abnormalities. We also examined cardiac responsiveness to exogenous Ang II and...
showed that GC-A protects the heart by inhibiting cardiac AT1A-mediated hypertrophy and interstitial fibrosis.

**Methods**

**Animals and Treatments**

All experimental procedures were performed according to Kyoto University standards for animal care. GC–KO and AT1A–KO mice were generated by methods described previously.15,17 The genetic background of the original GC–KO and AT1A–KO mice was C57BL/6. Wild-type (WT), AT1A–KO, GC–KO–A, and double-KO mice used in the present study were generated from heterozygous mice after crossing of single GC–KO mice and AT1A–KO mice. All comparisons were made among littermates. Male mice 16 weeks old were examined. Pharmacological treatments were begun when the mice were 12 weeks old. CS-866, an AT1 antagonist (gift from Sankyo Co Ltd; 10 mg · kg⁻¹ · d⁻¹, suspended in 0.5% carboxymethyl cellulose sodium salt solution) was given orally by gavage once a day for 4 weeks. A subpressor dose of Ang II (0.1 mg · kg⁻¹ · d⁻¹, dissolved in 0.01 mol/L acetic acid) was infused subcutaneously for 2 weeks with an osmotic minipump (model 2002, Alza Corp). 6-Hydroxydopamine (6-OHDA, 100 mg/kg, dissolved in saline; Sigma) was injected intraperitoneally twice over 5 to 6 days for 4 weeks. Control mice were given only vehicle.

**Measurement of BP and Heart Rate**

Systolic BP (SBP) and heart rate (HR) were measured in conscious mice by the tail-cuff method (Softtron Co Ltd).15,17

**Plasma Ang II Determination**

Blood samples were rapidly withdrawn from mice under ether anesthesia and immediately centrifuged to isolate the plasma, which was then stored at −20°C until determination of Ang II concentrations with a radioimmunoassay.

**Determination of Heart and Left Ventricular Weights and Interstitial Fibrosis**

Hearts were dissected out, the weights of the whole heart and left ventricle were measured, and the ratios of those weights to the body weight (HW/BW and LVW/BW) were calculated and used as an index of ventricular hypertrophy. The left ventricles were then fixed in 10% formalin and prepared for routine histology. To determine the degree of collagen fiber accumulation, we randomly selected 20 fields in 3 individual sections and calculated the ratio of the areas of van Gieson–stained interstitial fibrosis to the total left ventricular area using KS400 image system (Zeiss).

**Analysis of mRNA**

Total mRNA was prepared from the left ventricle by use of TRIzol (Life Technologies Inc). Expression of mRNAs encoding ANP, BNP, AT1A, ACE, angiotensinogen, transforming growth factor (TGF)-β1, TGF-β2, collagen I, and collagen III was evaluated with quantitative reverse transcription–polymerase chain reaction with the appropriate primers in a ABI PRISM 7700 Sequence Detector (Applied Biosystems). To verify that equal amounts of mRNA were subjected to reverse transcription–polymerase chain reaction, GAPDH mRNA was also amplified by use of the same method with specific primers and probe (Applied Biosystems).

**Statistical Analysis**

All results are expressed as mean±SEM. Data were analyzed by 1-factor ANOVA. If a statistically significant effect was found, the Newman-Keuls test was performed to isolate the difference between the groups. Values of P<0.05 were considered statistically significant.

**Results**

**Effects of AT1A Deletion on HR, SBP, HW/BW, LVW/BW, and Interstitial Fibrosis**

There was no significant difference in HR among genotypes (WT, 631.6±22.3; AT1A–KO, 592.4±14.0; GC–KO–A, 602.2±19.6; and double-KO, 584.1±12.5 bpm). GC–KO–A induced significant increases in SBP, HW/BW, and LVW/BW. Genetic deletion of AT1A similarly decreased SBP in WT (by 26.2%) and GC–KO (by 20.6%) background (Figure 1a). In contrast, it showed stronger inhibitions on HW/BW and LVW/BW in GC–KO (by 28.4% and 35.4%, respectively) than in WT (by 9.3% and 12.9%, respectively) background (Figure 1b and c). Left ventricular interstitial fibrosis was 7-fold higher in GC–KO–A than in WT mice, whereas fibrosis in AT1A–KO mice was similar to that in WT mice (Figure 1, d and e), although fibrosis in double-KO mice was still higher than in WT but was 58.9% lower than in GC–KO–A mice. Thus, AT1A–KO attenuated the hypertension, cardiac hypertrophy, and fibrosis otherwise seen in GC–KO–A mice. Interestingly, the effects of AT1A deletion on cardiac remodeling were more marked in GC–KO–A mice than in WT mice, whereas those on SBP were comparable among genotypes.

**Ventricular Expression of mRNAs Encoding Angiotensinogen, ACE, AT1A, ANP, BNP, Collagen I, Collagen III, TGF-β1, and TGF-β2**

We observed no significant difference between plasma Ang II levels in WT and GC–KO mice (92.4±8.9 and 90.9±16.2 pg/mL, respectively). Furthermore, we found that expression levels of ventricular angiotensinogen, ACE, and AT1A mRNA were comparable between WT and GC–KO mice (Figure 2, a through c). Therefore, it appears that GC-A does not affect plasma levels of Ang II or its receptor expression in the heart. In contrast, AT1A–KO significantly decreased angiotensinogen mRNA in both WT and GC–KO–A animals (Figure 2a).

ANP gene expression is increased by a variety of hypertrophic stimuli,19 and both the expression and secretion of BNP are elevated in patients with cardiac hypertrophy.20 When we analyzed ANP and BNP mRNA levels in the left ventricles of GC–KO–A and WT mice, we found their expression to be significantly elevated in the former (Figure 3, a and b), which is consistent with the cardiac hypertrophy seen in those animals. AT1A–KO was associated with significantly lower ANP and BNP expression in both GC-A and WT mice (Figure 3, a and b). Because TGF-β1 is reportedly involved in Ang II–induced synthesis of collagen,21,22 we also analyzed the left ventricular expression of collagen I, collagen III, TGF-β1, and TGF-β2 mRNAs. Transcription of all 4 was higher in GC–KO–A than in WT mice; consistent with the observed reduction in fibrosis, their expression in double-KO mice was decreased to the same levels as those in AT1A–KO mice, suggesting that the overexpression of these genes is almost completely AT1A-dependent (Figure 3, c through f).

**Effects of AT1 Blockade on SBP, HW/BW, LVW/BW, and Interstitial Fibrosis**

We also examined the effects of chronic administration of CS-866 on SBP, HW/BW, LVW/BW, and fibrosis and found
that the effects of CS-866 were similar to those of AT1a-KO (Figure 4, a through e). Furthermore, as with genetic deletion, pharmacological blockade of AT1 also appeared to affect myocardial hypertrophy and fibrosis more markedly in GC-A–KO than in WT mice.

To clarify whether the aforementioned effects of AT1 blockade reflected prevention or amelioration of the abnormalities seen in GC-A–KO mice, we compared SBP, HW/BW, LVW/BW, and fibrosis in 12- and 16-week-old WT and GC-A–KO mice receiving no other treatment. All 4 parameters were elevated in GC-A–KO mice at both times, and there was no significant difference between them at either time (Figure 5, a through d). Thus, the AT1 blocker ameliorated the hypertension, myocardial hypertrophy, and fibrosis that were already established in GC-A–KO mice.

**SBP and Cardiac Responsiveness to Exogenous Ang II**

Considering the lack of difference in mRNA levels of angiotensinogen, ACE, and AT1a between WT and GC-
by AT1A-KO and CS-866, it did not induce any reduction of HW/BW and cardiac fibrosis in either genotype (data not shown), supporting the concept that cardiac remodeling in GC-A–KO mice is independent of BP.

**Comparison of Effects of AT1A-KO, AT1 Blockade, and Ang II Infusion on SBP, HW/BW, and Cardiac Fibrosis**

AT1A-KO and AT1 blockade significantly lowered SBP in WT and GC-A–KO mice, indicating the important role of AT1A in maintenance of BP in both WT and GC-A–KO mice. However, the responsiveness of SBP to AT1A deletion or AT1 blocker was similar in both types (Figure 7, a through c), suggesting that specific elevation of BP in GC-A–KO mice is independent of AT1A signaling. Conversely, the HW/BW and cardiac fibrosis in GC-A–KO mice were more sensitive to the treatments than those in WT mice, suggesting the dependency of cardiac remodeling on AT1A signaling (Figure 7, a through c).

**Discussion**

In the present study, we demonstrate that GC-A disruption-induced cardiac hypertrophy and interstitial fibrosis are markedly inhibited by AT1A-KO or pharmacological blockade of AT1, implicating the involvement of AT1A in the cardiac remodeling. Furthermore, in the absence of GC-A, exogenous Ang II greatly exacerbates cardiac remodeling, suggesting that GC-A suppresses cardiac responsiveness to Ang II.

As reported previously, mice deficient for GC-A display hypertension and cardiac abnormalities,15,16 suggesting the important roles of GC-A in controlling BP and protecting the heart from excessive remodeling. However, it remains to be clarified what systems promoting cardiac remodeling were inhibited by GC-A. Ang II is a potent growth stimulator in cardiomyocytes and in fibroblasts21,22 in vitro, and an important role of local Ang II signaling is suggested in establishment of cardiac remodeling.23 AT1A is crucially involved in the hypertensive and hypertrophic effects of Ang II. To examine the role of Ang II signaling in the cardiovascular phenotypes of GC-A–deficient mice, we crossed them with an AT1A-deficient strain, yielding double-KO mice, which exhibited lower BP and HW/BW and reduced fibrosis compared with GC-A–deficient mice (Figure 1). Although the effects of AT1A-KO on SBP were comparable in WT and GC-A–KO mice, the reductions in HW/BW and fibrosis induced by AT1A-KO or AT1 blockade were more marked in GC-A–KO mice (Figure 7, a and b). Therefore, we speculated that cardiac AT1A signaling is enhanced in the absence of GC-A.

Previous studies provide circumstantial evidence of counterregulation by the natriuretic peptide system and RAS.24 Cardiomyocytes are the main source of ANP and BNP.11,15 GC-A, their receptor, is also expressed in cardiomyocytes25 and possibly in cardiac fibroblasts26. Likewise, components of the RAS have been demonstrated in the heart.27 In fact, we detected transcription of angiotensinogen, ACE, and AT1A in the cardiac ventricles, as shown in Figure 2. We initially speculated that cardiac Ang II was upregulated in GC-A, their receptor, is also expressed in cardiomyocytes25 and possibly in cardiac fibroblasts26. Likewise, components of the RAS have been demonstrated in the heart.27 In fact, we detected transcription of angiotensinogen, ACE, and AT1A in the cardiac ventricles, as shown in Figure 2. We initially speculated that cardiac Ang II was upregulated in GC-A–KO mice. That proved not to be the case, however; nor did we detect a difference in AT1A expression, which suggests that it

**Effects of Decreased BP on HW/BW and Cardiac Fibrosis**

To further clarify the influences of BP decline itself on cardiac hypertrophy and fibrosis in GC-A mice, we adapted 6-OHDA for chemical sympathectomy to lower BP.18 6-OHDA significantly decreased SBP in the same manner in WT and GC-A–KO mice (WT control, 115.9 ± 2.3; WT 6-OHDA, 101.8 ± 1.9; GC-A–KO control, 140.3 ± 3.0; and GC-A–KO 6-OHDA, 123.0 ± 6.3 mm Hg). Although this decline in GC-A–KO mice was comparable to that induced

---

**Figure 3.** Overexpression of ANP (a), BNP (b), TGF-β1 (c), TGF-β2 (d), collagen I (e), and collagen III (f) mRNAs in GC-A–KO mice was markedly inhibited by targeted deletion of AT1A (n = 5–9). Levels in WT mice were arbitrarily assigned a value of 1.0; all values are mean ± SEM. *P < 0.05.

---

- **Figure a**: Graph showing the overexpression of ANP in WT, AT1A-KO, GC-A-KO, and DMSO-KO mice.
- **Figure b**: Graph showing the overexpression of BNP in WT, AT1A-KO, GC-A-KO, and DMSO-KO mice.
- **Figure c**: Graph showing the overexpression of TGF-β1 in WT, AT1A-KO, GC-A-KO, and DMSO-KO mice.
- **Figure d**: Graph showing the overexpression of TGF-β2 in WT, AT1A-KO, GC-A-KO, and DMSO-KO mice.
- **Figure e**: Graph showing the overexpression of collagen I in WT, AT1A-KO, GC-A-KO, and DMSO-KO mice.
- **Figure f**: Graph showing the overexpression of collagen III in WT, AT1A-KO, GC-A-KO, and DMSO-KO mice.
is Ang II–induced postreceptor signaling that differs in GC-A–KO and WT mice. Therefore, we next examined the responsiveness to Ang II in GC-A–KO mice.

To rule out the effect of BP change, we chose Ang II at a subpressor dose. In WT mice, the infusion increased neither hypertrophy nor fibrosis. However, to our surprise, it augmented cardiac hypertrophy and fibrosis of GC-A–KO mice (Figure 6, b through d). The heart of GC-A–KO mice is much more responsive to Ang II infusion than that of WT mice (Figure 6c), suggesting that GC-A inhibits Ang II signaling at a postreceptor level, thereby suppressing cardiac remodeling independently of BP. The fact that decline of BP by another kind of depressor agent, 6-OHDA, did not influence cardiac hypertrophy and fibrosis in GC-A supports the hypothesis that cardiac remodeling in GC-A–KO mice is independent of BP.

Knowles et al\textsuperscript{28} reported that an increase in cardiac afterload caused by transverse aortic constriction resulted in a 55% increase in LVW/BW of GC-A–KO mice, but only an 11% increase in WT mice (Figure 7c), suggesting that GC-A inhibits Ang II signaling at a postreceptor level, thereby suppressing cardiac remodeling independently of BP. The fact that decline of BP by another kind of depressor agent, 6-OHDA, did not influence cardiac hypertrophy and fibrosis in GC-A supports the hypothesis that cardiac remodeling in GC-A–KO mice is independent of BP.

Knowles et al\textsuperscript{28} also demonstrated that both the basal activities of mitogen-activated protein kinases and their induction by pressure overload were not different between GC-A–KO and WT mice and speculated that the relative activation of mitogen-activated protein kinases does not appear to be a controlling factor in the hypertrophic response in GC-A–KO mice caused by pressure overload.\textsuperscript{28} Further examination is necessary to determine the molecular effectors responsible for the cross-talk between the GC-A and AT\textsubscript{1A} pathways in cardiac remodeling in vivo.

Figure 4. Pharmacological blockade of AT\textsubscript{1} with CS-866 ameliorated hypertension, cardiac hypertrophy, and fibrosis seen in GC-A–KO mice. (a) SBP; (b) HW/BW; (c) LVW/BW; (d) representative examples of fibrosis; (e) left ventricular fibrosis without (−) or with (+) CS-866. Values are mean±SEM (n=5–8). *P<0.05.
TGF-β is a potent stimulator of extracellular matrix protein (ECMP) synthesis (eg, collagen and fibronectin). Ang II appears to stimulate synthesis of ECMPs in cardiac fibroblasts, vascular smooth muscle cells, and renal mesangial cells through induction of TGF-β expression. In the present study, AT1A deletion or AT1 blockade markedly attenuated the cardiac fibrosis seen in GC-A KO mice (Figure 1, d and e, and Figure 4, d and e), along with the increased transcription of TGF-β1, TGF-β3, collagen I, and collagen III (Figure 3, c through e). These results further support the hypothesis that AT1A is involved in the fibrosis of GC-A–KO mice.

Our findings suggest that the GC-A–ligand system is an endogenous mechanism that protects the heart from AT1A-mediated remodeling. Recently, Nakayama et al described a functional mutation in the 5′-flanking region of human GC-A gene that is associated with essential hypertension and cardiac hypertrophy. GC-A gene expression is most likely diminished in these patients because of the mutation, predisposing them to cardiac hypertrophy and fibrosis like that seen in GC-A–KO mice. The activation of cardiac GC-A by natriuretic peptides or related drugs might therefore represent a new approach with which to improve treatment of cardiac structural abnormalities. The present results also suggest that blockade of AT1 or Ang II signaling using an AT1 blocker or ACE inhibitor would be the treatment of choice to prevent the cardiac hypertrophy and fibrosis in patients with lower expression level of GC-A.

In conclusion, our results provide direct evidence that GC-A inhibits cardiac remodeling partially via antagonizing AT1A signaling. The findings offer new insight into endogenous mechanisms for protection of the heart.

**Figure 5.** SBP (a), HW/BW (b), LVW/BW (c), and left ventricular fibrosis (d) at 12 and 16 weeks of age. Values are mean±SEM (n=7–9). *P<0.05.

**Figure 6.** Enhanced cardiac responsiveness to a subpressor dose of Ang II in GC-A KO mice. (a) SBP; (b) HW/BW; (c) LVW/BW; and (d) left ventricular fibrosis. Values are mean±SEM (n=7–9). *P<0.05.

**Figure 7.** Percentage changes in SBP, HW/BW, LVW/BW, and left ventricular fibrosis induced by targeted deletion (a) or pharmacological blockade (b) of AT1A (inhibition) and stimulation by a subpressor dose of Ang II (c) (enhancement). Data were calculated from the results shown in Figures 1, 4, and 6.
**Acknowledgments**

This work was supported in part by research grants from the Japanese Ministry of Education, Science, and Culture; the Japanese Ministry of Health and Welfare; the Japanese Society for the Promotion of Science “Research for the Future” program (JSPS-RFTP96I00204 and JSPS-RFTP98L00801); the Uehara Memorial Foundation; and the Smoking Research Foundation. We also thank Makoto Mukai and Itone Makino for their excellent secretarial assistance and Mika Inoue for her technical assistance. Dr Li is a foreign research fellow of the Japan Society for the Promotion of Science.

**References**


Guanlyl Cyclase-A Inhibits Angiotensin II Type 1A Receptor-Mediated Cardiac Remodeling, an Endogenous Protective Mechanism in the Heart
Yuhao Li, Ichiro Kishimoto, Yoshihiko Saito, Masaki Harada, Koichiro Kuwahara, Takehiko Izumi, Nobuki Takahashi, Rika Kawakami, Keiji Tanimoto, Yasuaki Nakagawa, Michio Nakanishi, Yuichiro Adachi, David L. Garbers, Akiyoshi Fukamizu and Kazuwa Nakao

Circulation. 2002;106:1722-1728; originally published online September 3, 2002; doi: 10.1161/01.CIR.0000029923.57048.61
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/106/13/1722

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/